Satoh Atsushi, Miwa Hiroshi, Daimaru Osami, Imai Norikazu, Hiramatsu Akihito, Yamamoto Hidesuke, Shikami Masato, Imamura Akira, Mihara Hidetsugu, Nitta Masakazu
Division of Haematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Aichi, Japan.
Eur J Haematol. 2003 Aug;71(2):130-2. doi: 10.1034/j.1600-0609.2003.00103.x.
We describe a patient who presented with aplastic anaemia associated with the Philadelphia (Ph1) chromosome during immunosuppressive therapy and who subsequently developed myelodysplastic syndrome (MDS) with monosomy 7. Initially the patient had hypocellular fatty marrow without leukaemic blasts or dysplastic features. Chromosome analysis showed 46, XY, t(9;22)(q34;q11) during immunosuppressive therapy, but no leukaemic transformation was detected. The patient showed gradual haematologic improvement and became transfusion independent. Thereafter, bone marrow dysplasia with monosomy 7 progressed following transfusion independence. These findings indicate that multiple cytogenetic evolutions occur in aplastic anaemia during immunosuppressive therapy, and that Ph1 chromosome may play a role in bone marrow suppression rather than development of leukaemia.
我们描述了一名患者,该患者在免疫抑制治疗期间出现与费城(Ph1)染色体相关的再生障碍性贫血,随后发展为伴有7号染色体单体的骨髓增生异常综合征(MDS)。最初,患者骨髓细胞减少且为脂肪髓,无白血病原始细胞或发育异常特征。染色体分析显示在免疫抑制治疗期间为46, XY, t(9;22)(q34;q11),但未检测到白血病转化。患者血液学逐渐改善,不再依赖输血。此后,在不再依赖输血后,伴有7号染色体单体的骨髓发育异常进展。这些发现表明,在免疫抑制治疗期间再生障碍性贫血会发生多种细胞遗传学演变,并且Ph1染色体可能在骨髓抑制而非白血病发生中起作用。